The Impact of Amino Acids on Postprandial Glucose and Insulin Kinetics in Humans: A Quantitative Overview

Bart van Sloun 1,2,* , Gijs H. Goossens 1,3, Balazs Erdos 1,2*, Michael Lenz 4,5, Natal van Riel 6 and Ilja C. W. Arts 1,2,7

1 TiFN, 6700 AN Wageningen, The Netherlands; g.goossens@maastrichtuniversity.nl (G.H.G.); balazs.erdos@maastrichtuniversity.nl (B.E.); ilja.arts@maastrichtuniversity.nl (I.C.W.A.)
2 Maastricht Centre for Systems Biology (MaCSBio), Maastricht University, 6200 MD Maastricht, The Netherlands
3 Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, 6200 MD Maastricht, The Netherlands
4 Institute of Organismic and Molecular Evolution, Johannes Gutenberg University Mainz, D 55099 Mainz, Germany; michael.l.lenz@googlemail.com
5 Preventive Cardiology and Preventive Medicine-Centre for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, D 55131 Mainz, Germany
6 Department of Biomedical Engineering, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands; N.A.W.v.Riel@tue.nl
7 Department of Epidemiology, CARIM School for Cardiovascular Diseases, Maastricht University, 6200 MD Maastricht, The Netherlands
* Correspondence: b.vansloun@maastrichtuniversity.nl; Tel.: +31-433881127

Received: 2 October 2020; Accepted: 20 October 2020; Published: 21 October 2020

Abstract: Different amino acids (AAs) may exert distinct effects on postprandial glucose and insulin concentrations. A quantitative comparison of the effects of AAs on glucose and insulin kinetics in humans is currently lacking. PubMed was queried to identify intervention studies reporting glucose and insulin concentrations after acute ingestion and/or intravenous infusion of AAs in healthy adults and those living with obesity and/or type 2 diabetes (T2DM). The systematic literature search identified 55 studies that examined the effects of l-leucine, l-isoleucine, l-lysine, l-asparagine, l-glutamine, l-arginine, l-lysine, glycine, l-proline, l-phenylalanine, branched-chain AAs (i.e., l-leucine, l-isoleucine, and l-valine), and multiple individual l-AAs on glucose and insulin concentrations. Oral ingestion of most individual AAs induced an insulin response, but did not alter glucose concentrations in healthy participants. Specific AAs (i.e., leucine and isoleucine) co-ingested with glucose exerted a synergistic effect on the postprandial insulin response and attenuated the glucose response compared to glucose intake alone in healthy participants. Oral AA ingestion as well as intravenous AA infusion was able to stimulate an insulin response and decrease glucose concentrations in T2DM and obese individuals. The extracted information is publicly available and can serve multiple purposes such as computational modeling.

Keywords: systematic review; amino acids; kinetics; dynamics; glucose homeostasis; insulin secretion; insulin sensitivity; obesity; type 2 diabetes; time series data

1. Introduction

Glucose is a key substrate for many different types of cells and tissues, and as such plays an important role in human metabolism [1]. Blood glucose concentrations are tightly regulated to prevent hypoglycemia and hyperglycemia, thereby ensuring normal body functions. Glucagon and adrenalin...
are the key hormones responsible for elevating blood glucose concentration (for example during fasting or exercise), whereas insulin lowers blood glucose concentrations (for example following meal intake) [2]. This complex regulatory system involves various organs, including the gut, pancreas, liver, adipose tissue and skeletal muscle. Impairment of glucose homeostasis increases the risk of developing chronic cardiometabolic diseases such as type 2 diabetes mellitus (T2DM) and cardiovascular disease, highlighting the importance of adequate control of blood glucose concentrations [3].

Amino acids (AAs) are involved in the regulation of insulin secretion through their effects on β-cells, causing a rise in the ATP/ADP ratio, suppression of ATP-sensitive potassium channels and activation of voltage-gated Ca\(^{2+}\) channels [4]. The resulting calcium influx allows exocytosis of insulin granules from the β-cells. The insulinotropic effect of AA administration in humans was studied in the 1960s by Floyd et al. [5,6]. An intravenous infusion of an AA mixture, consisting of essential l-AA, increased plasma insulin concentration and subsequently lowered blood glucose concentrations in healthy people [5]. A similar response was also demonstrated following infusion of single AAs [5,6]. Interestingly, however, there seemed to be large differences in the capacity of the various AAs to stimulate insulin secretion [5]. A synergistic effect of simultaneous glucose and AA ingestion was found in several studies, where co-ingestion of AAs with glucose increased insulin secretion more than the sum of the individual effects [6–9]. The insulinotropic effect of AA administration has also been demonstrated in patients with T2DM. For example, co-ingestion of a protein hydrolysate/AA mixture with carbohydrates induced a more pronounced increase in plasma insulin concentrations compared to intake of carbohydrates alone, not only in healthy people but also in patients with T2DM [9]. Of note, the metabolic phenotype may influence the magnitude of the glucose and insulin responses following ingestion of AAs.

Despite decades of research, there is no quantitative overview available that describes the effects of individual AAs on glucose and insulin kinetics in individuals with different metabolic phenotypes. These data are needed as the type and amount of AA intake, the administration route (i.e., oral versus intravenous) and study population seems to affect the insulin and glucose responses to AAs. We hypothesize that AAs exert distinct effects on glucose and insulin dynamics, which are further influenced by the metabolic phenotype as well as route of administration. A better mechanistic understanding would therefore allow for more targeted nutrition studies. This information could also aid in the improvement of physiology-based computational models of the glucose regulatory system, which have been developed and approved for pre-clinical research [10]. Therefore, we performed a systematic literature search and extracted the original data, which we made publicly available, to obtain better insight into the quantitative acute effects of individual AAs on postprandial glucose and insulin dynamics in humans, taking the metabolic phenotype into account.

2. Materials and Methods

Details of the systematic review were registered in the PROSPERO International Prospective Register of Systematic Reviews (registration number CRD42020155067).

2.1. Search Strategy

Studies assessing the quantitative acute effects of AAs on postprandial plasma glucose and insulin concentrations were retrieved from the PubMed database between February 2018 and February 2020. The search strategy contained multiple (combinations of) main keywords appropriate for the topic of interest (“Amino acids” AND “Postprandial” AND (“Glucose” OR “Insulin”)). The detailed search strategy is provided in the Supplemental File S1. Searches were not limited by article publication date. From the identified articles, the titles and abstract were assessed first, and if considered relevant for the present systematic review, the full text of the article was examined in detail.
2.2. Selection Criteria

Criteria for study inclusion were set according to the Population-Intervention-Comparator-Outcomes-Study design (PICOS) format (Table 1). Eligible studies included healthy adults as well as people living with overweight/obesity and T2DM. Only acute studies that evaluated the effects of oral AA ingestion and/or intravenous AA administration on glucose and insulin concentrations were included. Studies had to be original research and be written in English. Labels were added to the eligible articles, describing the subject characteristics, type of AA and route of AA administration.

| Inclusion Criteria | Exclusion Criteria |
|-------------------|--------------------|
| **Population**    | **Healthy adults** |
|                   | **Adults with T2DM** |
|                   | **Adults with overweight/obesity** |
|                   | **Children and adolescents** |
|                   | **Pregnant females** |
|                   | **Animals** |
| **Intervention**  | **Oral AA ingestion** |
|                   | **Intravenous AA infusion** |
| **Comparison**    | **Control (i.e., water, saline)** |
| **Outcomes**      | **Glucose concentrations (repeated measurements)** |
|                   | **Insulin concentrations (repeated measurements)** |
| **Trial design**  | **Intervention study** |
| **Type of publication** | **Original research articles** |
|                   | **Published in a peer-reviewed international journal, regardless of publication year** |

T2DM: Type 2 diabetes mellitus, AA: Amino acid.

2.3. Data Extraction

Data were extracted from eligible studies and entered into an Excel (2016, Microsoft Corporation) spreadsheet. The following items were extracted: bibliographic details (title; authors; year; journal), study population (health status; number of subjects; sex; age; body mass index (BMI); weight), intervention (type; dose; method of administration; duration), study design and the outcome measurements of interest (glucose concentrations; insulin concentrations). In the absence of exact numerical values for the outcome measurements of interest in the original articles, figures were digitized using graph digitizing software (Graph Grabber version 2.0, Quintessa). After loading the figures in the digitizing software, the x- and y-axis was set to correctly map the image pixels to the corresponding data values in the figure. Data points (i.e., means and their corresponding standard errors or standard deviations) were determined by manually clicking them and were subsequently stored in Excel data sheets for further processing. The extracted data from the 55 studies is publicly available (https://doi.org/10.34894/RNZl0A) and can serve multiple purposes such as computational modeling.

2.4. Data Processing

The extracted data was imported into MATLAB [11]. Measurement units were converted to mg/dL for glucose and µU/mL for insulin. The iAUC was calculated according to the trapezoidal rule in MATLAB, and normalized to one minute by dividing with the time span of the response. The time to glucose and insulin peaks and their concentrations were identified from the extracted data by selecting the data-points with the highest glucose and insulin concentrations, and their corresponding time points in MATLAB. No statistical analysis was performed. The mention of significance in this review refers to the statistical analysis performed in the original studies.
3. Results

3.1. Literature Search

The PubMed search identified 10,311 unique records (Figure 1). Titles and/or abstracts were screened, which resulted in the exclusion of 9,678 studies. Three additional records were identified through searching reference lists. The remaining 636 full-text articles were retrieved and assessed for eligibility based on the selection criteria (Table 1). From these full-text articles, a total of 548 articles were excluded. Reasons for exclusion were related to the target population, intervention, time-scale, outcome parameters, and article language. An additional 33 articles were excluded due to accessibility restrictions and could not be retrieved via the university library. Thus, a total of 55 studies were included in the analysis. In the studies, the effects of L-leucine ($n = 6$), L-isoleucine ($n = 1$), L-alanine ($n = 6$), L-glutamine ($n = 1$), L-arginine ($n = 28$), L-lysine ($n = 1$), L-proline ($n = 1$), L-phenylalanine ($n = 1$), L-glutamate ($n = 3$), branched-chain AAs (BCAAs) (i.e., L-leucine, L-isoleucine, and L-valine) ($n = 4$), and multiple L-AAs ingested separately (i.e., L-leucine, L-arginine, L-lysine, and L-phenylalanine) ($n = 1$) on postprandial glucose and insulin concentrations were determined. When mentioning different AAs throughout the present manuscript, with the exception of glycine that has no enantiomers because it has two hydrogen atoms attached to the central carbon atom, we refer to the L-isoforms of the respective AA.

3.2. Leucine

Leucine study details are provided in Table 2 (section A). The time series data and the calculated kinetic parameters are visualized in Figure 2. The effect of oral leucine intake (Figure 2A) has only been examined in healthy individuals [8,12,13]. Two out of the three studies showed increased insulin concentrations (iAUC range, 0.85 to 0.95 µU/mL/min) from baseline [12] and compared to a water control group (0.28 µU/mL/min) [8]. Glucose concentrations were unchanged compared to the water control group. The study with the lowest oral leucine dose showed decreased insulin (iAUC, −1.22 µU/mL/min) [13]. Here, the insulin reached a peak (5.35 µU/mL at 15 min), followed by a decrease below baseline values.
Table 2. Characteristics of the 55 included studies.

| Section | First Author, Year of Publication | n  | Age (yrs) | BMI (kg/m²) | Body Weight (kg) | Lean Body Mass (kg) | Subject Condition | Group | Dose | Route of Administration | Duration (min) | Glucose Measurements | Insulin Measurements | Blood Sampling |
|---------|----------------------------------|----|-----------|-------------|-----------------|-------------------|-------------------|-------|------|------------------------|----------------|---------------------|---------------------|---------------|
| A       | Kalogeropoulos, 2008 [17]        | 11 | 22.9      |             | -              | -                 | Healthy           | Lysine | 15 g | IV                      | 0–30           | Blood               | Plasma              | Forearm vein   |
|         |                                 | 11 | 22.9      |             | -              | -                 | Healthy           | Arginine | 15 g | IV                      | 0–30           | Blood               | Plasma              | Forearm vein   |
|         |                                 | 11 | 22.9      |             | -              | -                 | Healthy           | Phenylalanine    | 15 g | IV                      | 0–30           | Blood               | Plasma              | Forearm vein   |
|         | Wilkenson, 2013 [12]             | 7  | 21 ± 0.3  | 25 ± 0.6    | -               | -                 | Healthy           | Lysine | 7 g  | Oral                    | Acute          | Serum               | Serum               | Antecubital or forearm vein |
|         | Yoshi, 2018 [13]                 | 10 | 25 ± 1    |             | 65.8 ± 1.5     | -                 | Healthy           | Lysine | 2 g  | Oral                    | Acute          | Blood               | Plasma              | Antecubital or forearm vein |
|         | Alsnerad, 1982 [14]              | 13 | 27 ± 1    |             | 68 ± 2         | -                 | Healthy           | Lysine | 5.6 g | IV                      | 0–300          | Plasma              | Plasma              | Arterial blood samples |
|         | Eriksson, 1983 [15]              | 18 | 26 ± 1    | 22.9         | 76 ± 2         | -                 | Healthy           | Lysine | 5.9 g | IV                      | 0–150          | Plasma              | Plasma              | Arterial blood samples |
|         | Sherwin, 1978 [16]               | 11 | 21–35     |             | -              | -                 | Healthy           | Lysine | 3.7 g | IV                      | 0–180          | Plasma              | Plasma              | Antecubital vein  |
| B       | Nuttall, 2008 [18]               | 9  | 33.8 ± 6.5| 28 ± 6.6    | 81 ± 20.8       | 56.5 ± 12.3       | Healthy           | Isoleucine       | 7.4 g | Oral                    | Acute          | Plasma              | Plasma              | Antecubital vein  |
|         |                                 | 9  | 33.8 ± 6.5| 28 ± 6.6    | 81 ± 20.8       | 56.5 ± 12.3       | Healthy           | Isoleucine+Glucose| 7.4 g | Oral                    | Acute          | Plasma              | Plasma              | Antecubital vein  |
|         |                                 | 9  | 33.8 ± 6.5| 28 ± 6.6    | 81 ± 20.8       | 56.5 ± 12.3       | Healthy           | Glucose | 25 g | Oral                    | Acute          | Plasma              | Plasma              | Antecubital vein  |
|         |                                 | 9  | 33.8 ± 6.5| 28 ± 6.6    | 81 ± 20.8       | 56.5 ± 12.3       | Healthy           | Water            | -    | Oral                    | Acute          | Plasma              | Plasma              | Antecubital vein  |
| C       |Rossini, 1975 [19]                | 6  | 20–32     | -           | -              | -                 | Healthy           | Alanine | 10 g | Oral                    | Acute          | Blood               | Serum               | Antecubital vein  |
|         |                                 | 6  | 20–32     | -           | -              | -                 | Healthy           | Alanine | 10 g | IV                      | 0–60           | Blood               | Serum               | Antecubital vein  |
|         |Rose, 1977 [20]                   | 13 | 23 ± 4    | -           | 59.5 ± 5.6     | -                 | Healthy           | Alanine | 11.9 g | Oral                    | Acute          | Plasma              | Plasma              | Antecubital vein  |
|         |Sato, 1980 [21]                   | 5  | 25        | -           | -              | -                 | Healthy           | Alanine | 64.6 g | 2                      | Oral           | Acute               | Blood               | Antecubital vein  |
|         |Genuth, 1974 [22]                 | 10 | 20–46     | -           | -              | -                 | Healthy           | Alanine | 33.8 g | 2                      | Oral           | Acute               | Plasma              | Antecubital vein  |
|         |                                 | 10 | 20–46     | -           | -              | -                 | Healthy           | Alanine | 6.8 g | 2                      | Oral           | Acute               | Plasma              | Antecubital vein  |
|         |                                 | 10 | 20–72     | -           | -              | -                 | Healthy           | T2DM       | 37.5 g | 2                      | Oral           | Acute               | Plasma              | Antecubital vein  |
|         |                                 | 10 | 40–71     | -           | -              | -                 | Healthy           | T2DM       | 8.2 g | 2                      | Oral           | Acute               | Plasma              | Antecubital vein  |
|         |Genuth, 1973 [23]                 | 6  | 42.5 ± 9.3|             | 151 ± 39.6     | -                 | Obese             | Alanine | 50 g  | Oral                    | Acute          | Plasma              | Plasma              | Antecubital vein  |
|         |Asano, 1989 [24]                  | 9  | 21 ± 0.7  | 19.8 ± 0.3  | 53 ± 5         | -                 | Healthy           | Alamine       | 5.3 g  | IV                      | 0–2           | Plasma              | Plasma              | Forearm vein    |
|         |                                 | 6  | 28 ± 3.5  | 31.3 ± 3    | 89 ± 12        | -                 | Obese             | Alanine       | 8.9 g  | IV                      | 0–2           | Plasma              | Plasma              | Forearm vein    |
| Section | First Author, Year of Publication | n  | Age (yrs) | BMI (kg/m²) | Body Weight (kg) | Lean Body Mass (kg) | Subject Condition | Group  | Dose | Route of Administration | Duration (min) | Glucose Measurements | Insulin Measurements | Blood Sampling  |
|---------|----------------------------------|----|-----------|-------------|-----------------|-------------------|------------------|--------|------|------------------------|----------------|---------------------|---------------------|-----------------|
| D       | Greenfield, 2008 [25]            | 8  | 30 ± 5.8  | 21.9 ± 2.2  | 70.3 ± 8.6      | -                 | Healthy          | Glutamine | 30 g | Oral                      | Acute           | Plasma              | Plasma              | Antecubital vein |
|         |                                  | 8  | 30 ± 5.8  | 21.9 ± 2.2  | 70.3 ± 8.6      | -                 | Healthy          | Water     | 300 mL | Oral                      | Acute           | Plasma              | Plasma              | Antecubital vein |
|         |                                  | 8  | 38.5 ± 8  | 38.5 ± 6.5  | 120.6 ± 24.2    | -                 | T2DM             | Glutamine | 30 g | Oral                      | Acute           | Plasma              | Plasma              | Antecubital vein |
|         |                                  | 8  | 38.5 ± 8  | 38.5 ± 6.5  | 120.6 ± 24.2    | -                 | T2DM             | Water     | 300 mL | Oral                      | Acute           | Plasma              | Plasma              | Antecubital vein |
|         |                                  | 8  | 39 ± 9.8  | 34.5 ± 4.4  | 106 ± 14.8      | -                 | Obese            | Glutamine | 30 g | Oral                      | Acute           | Plasma              | Plasma              | Antecubital vein |
|         |                                  | 8  | 39 ± 9.8  | 34.5 ± 4.4  | 106 ± 14.8      | -                 | Obese            | Water     | 300 mL | Oral                      | Acute           | Plasma              | Plasma              | Antecubital vein |
| E       | Gannon, 2002 [26]                | 9  | 21–52     | 25.9 ± 0.5  | 75              | 61                | Healthy          | Arginine  | 10.6 g | Oral                      | Acute           | Plasma              | Serum              | Forearm vein    |
|         |                                  | 9  | 21–52     | 25.9 ± 0.5  | 75              | 61                | Healthy          | Glucose+Arginine| 25 g   | Oral                      | Acute           | Plasma              | Serum              | Forearm vein    |
|         | Tang, 2013 [27]                  | 8  | 30.5 ± 3.7| 21.0 ± 2.4  | 56.8 ± 6.8      | -                 | Healthy          | Arginine  | 30 g   | Oral                      | Acute           | Plasma              | Serum              | Forearm vein    |
|         |                                  | 8  | 30.5 ± 3.7| 21.0 ± 2.4  | 56.8 ± 6.8      | -                 | Healthy          | Arginine+Glucose| 30 g   | Oral                      | Acute           | Plasma              | Serum              | Forearm vein    |
|         |                                  | 8  | 30.5 ± 3.7| 21.0 ± 2.4  | 56.8 ± 6.8      | -                 | Healthy          | Glucose  | 30 g   | Oral                      | Acute           | Plasma              | Serum              | Forearm vein    |
|         | Giugliano, 1997 [28]            | 10 | 24 ± 1    | 23 ± 0.4    | 67 ± 1.8        | -                 | Healthy          | Arginine | 30 g   | IV              | 0–30            | Plasma              | Plasma              | Dorsal vein    |
|         | Coiro, 1997 [29]                 | 14 | 24–35     | -           | -               | -                 | Healthy          | Arginine | 30 g   | IV              | 0–30            | Blood               | -                  | Antecubital vein |
|         | Broglio, 2003 [30]              | 7  | 28.3 ± 3.1| 29.1 ± 0.9  | -               | -                 | Healthy          | Arginine | 34 g   | IV              | 0–30            | Blood               | Antecubital vein   |
|         |                                  | 7  | 28.3 ± 3.1| 29.1 ± 0.9  | -               | -                 | Healthy          | Glucose  | 3 mL   | IV              | 0–90            | Blood               | Blood              |
|         | Dela, 1990 [31]                 | 7  | 22        | 23.2        | 76              | -                 | Healthy-untrained| Arginine | 68.4 g  | IV              | 0–90            | Plasma              | Plasma              |
|         | Penny, 1970 * [32]              | 8  | -         | -           | 69.5 ± 14.3     | -                 | Healthy          | Arginine | 34 g   | IV              | 0–30            | Plasma              | -                  | Peripheral vein  |
|         | Levin, 1971 [33]                | 6  | 23–50     | -           | 69.5 ± 14.5     | -                 | Healthy          | Arginine | 20 g   | IV              | 0–20            | Blood               | -                  | Antecubital vein  |
|         | Bratusch-Marrain, 1979 [34]      | 9  | 21–42     | -           | -               | -                 | Healthy          | Arginine | 30 g   | IV              | 0–30            | Blood               | -                  | Glucose          |
|         | Imura, 1976 [35]                | 15 | -         | -           | -               | -                 | Healthy          | Arginine | 30 g   | IV              | 0–45            | Blood               | Plasma              | Antecubital vein  |
| First Author, Year of Publication | n  | Age (yrs) | BMI (kg/m²) | Body Weight (kg) | Lean Body Mass (kg) | Subject Condition | Group | Dose | Route of Administration | Duration (min) | Glucose Measurements | Insulin Measurements | Blood Sampling |
|-------------------------------------------------|----|----------|-------------|-----------------|--------------------|-------------------|-------|------|-------------------------|----------------|---------------------|-------------------|-----------------|
| Hasselblatt, 2006 [36]                           | 15 | 39       | 24.9        | -               | -                  | Healthy           | Arginine | 30 g | IV                       | 0–30          | Blood               | Plasma            | Glucose: capillary blood |
| Berger, 1974 [37]                                | 9  | -        | -           | -               | -                  | Healthy           | Arginine | 30 g | IV                       | 0–30          | Blood               | Plasma            | Forearm vein         |
| Dupre, 1968 [38]                                 | 13 | -        | -           | -               | -                  | Healthy           | Arginine | 15 g | IV                       | 0–40          | Blood               | Serum             | -               |
| Dupre, 1969 [39]                                 | 6  | 18–35    | -           | -               | -                  | Healthy           | Arginine | 3.9 g | IV                       | 0–40          | Blood               | Serum             | Forearm vein         |
| Dupre, 1969 [39]                                 | 6  | 18–35    | -           | -               | -                  | Healthy           | Arginine | 15 g | IV                       | 0–40          | Blood               | Serum             | Forearm vein         |
| Kimber, 2001 [40]                                | 5  | 58       | -           | -               | -                  | Healthy           | Arginine | 31.8 g² | IV                       | 0–30          | Plasma              | Plasma             | -               |
| Ohneda, 1972 [41]                                | 8  | -        | -           | -               | -                  | Healthy           | Arginine | 30 g | IV                       | 0–30          | Blood               | Plasma             | Brachial vein        |
| Efendic, 1974 [42]                               | 7  | 30.6 ± 4.4 | -          | -               | -                  | Healthy           | Arginine | 27.9 g² | IV                       | 0–30          | Blood               | Plasma             | Brachial vein        |
| Kawamori, 1981 [43]                              | 9  | 25–35    | -           | -               | -                  | Healthy           | Arginine | 32.3 g² | IV                       | 0–30          | Blood               | Plasma             | Antecubital vein     |
| Kimber, 1985 [45]                                | 7  | 46–70    | -           | -               | -                  | Healthy           | Arginine | 33.5 g² | IV                       | 0–30          | Blood               | Plasma             | Antecubital vein     |
| Sparks, 1967 [44]                                | 10 | 25 ± 1   | -           | 66 ± 3          | -                  | Healthy           | Arginine | 30 g | IV                       | 0–30          | Blood               | Serum             | Venous blood samples |
|                          | 6  | 57 ± 3   | -           | 66 ± 9          | -                  | T2DM              | Arginine | 30 g | IV                       | 0–30          | Blood               | Serum             | Venous blood samples |
| Kawamori, 1985 [45]                              | 9  | 25–30    | -           | -               | -                  | Healthy           | Arginine | 32.3 g² | IV                       | 0–30          | Blood               | Serum             | Venous blood samples |
|                          | 7  | 46–71    | -           | -               | -                  | T2DM              | Arginine | 32.3 g² | IV                       | 0–30          | Blood               | Serum             | Antecubital vein     |
| Maccario, 1996 [46]                              | 7  | 26–32    | 20.6 ± 1.3  | -               | -                  | Healthy           | Arginine | 27.2 g³ | IV                       | 0–30          | Plasma              | Serum             | Antecubital vein     |
|                          | 7  | 23–52    | 38.3 ± 2.6  | -               | -                  | Obese             | Arginine | 50.6 g³ | IV                       | 0–30          | Plasma              | Serum             | Antecubital vein     |
| Martella, 1996 [47]                              | 10 | 47.0 ± 0.8 | 28.1 ± 0.7 | 78 ± 2.9        | -                  | T2DM              | Arginine | 30 g | IV                       | 0–30          | Plasma              | Plasma             | Dorsal vein          |
| Raskin, 1976 [48]                                | 6  | 48       | -           | 85              | -                  | T2DM              | Arginine | 20 g | IV                       | 0–40          | Plasma              | Plasma             | Antecubital vein     |
| Maejima, 2002 [49]                               | 12 | 58.5 ± 3.3 | 57.0 ± 3.6 | -               | -                  | T2DM              | Arginine | 30 g | IV                       | 0–30          | Blood               | -                 | Glucose: capillary blood |
| Ohneda, 1975 [50]                                | 5  | 63.2 ± 5.9 | -          | -               | -                  | T2DM              | Arginine | 30 g | IV                       | 0–30          | Blood               | Plasma             | Antecubital vein     |
| Carpentier, 2001 [51]                            | 14 | 44.4 ± 2 | 36.2 ± 1.9  | -               | -                  | Obese             | Arginine | 49.3 g³ | IV                       | 0–30          | Plasma              | Serum             | Antecubital vein     |
| Maccario, 1997 [52]                              | 6  | -        | -           | -               | -                  | Obese             | Arginine | 5 g  | IV                       | 0–1           | Serum               | Serum             | Antecubital vein     |
| Walter, 1980 [53]                                | 5  | 26–40    | -           | 135–227         | -                  | Obese             | Arginine | 11 g | Oral                     | Acute          | Serum               | Serum             | Antecubital vein     |
| F Kalogeropoulou 2009 [54]                       | 13 | 30       | 26          | 80              | 60                 | Healthy           | Lysine     | 11 g | Oral                     | Acute          | Serum               | Serum             | Antecubital vein     |
|                            | 13 | 30       | 26          | 80              | 60                 | Healthy           | Lysine + Glucose | 11 g + 25 g | Oral                 | Acute          | Serum               | Serum             | Antecubital vein     |
|                            | 13 | 30       | 26          | 80              | 60                 | Healthy           | Glucose   | 25 g  | Oral                     | Acute          | Serum               | Serum             | Antecubital vein     |
### Table 2. Cont.

| Section | First Author, Year of Publication | n  | Age (yrs) | BMI (kg/m²) | Body Weight (kg) | Lean Body Mass (kg) | Subject Condition | Group | Dose | Route of Administration | Duration (min) | Glucose Measurements | Insulin Measurements | Blood Sampling |
|---------|----------------------------------|----|-----------|-------------|-----------------|--------------------|-------------------|-------|------|------------------------|----------------|-------------------|-------------------|------------------|
| G       | Gannon, 2002 [55]                | 9  | 21–52     | 25.9 ± 0.5  | 75              | 61                 | Healthy           | Glycine | 4.6 g | Oral                   | Acute          | Plasma            | Serum             | Forearm vein     |
|         |                                  | 9  | 21–52     | 25.9 ± 0.5  | 75              | 61                 | Healthy           | Glycine + Glucose| 4.6 g + 25 g | Oral                   | Acute          | Plasma            | Serum             | Forearm vein     |
|         |                                  | 9  | 21–52     | 25.9 ± 0.5  | 75              | 61                 | Healthy           | Glucose          | 25 g   | Oral                   | Acute          | Plasma            | Serum             | Forearm vein     |
|         |                                  | 9  | 21–52     | 25.9 ± 0.5  | 75              | 61                 | Healthy           | Water            |        | -                      |                |                   |                   |                  |
| Kasai, 1978 [56]                      | 19 | 20–70     | -          | -             | -                 | Healthy           | Glycine          |        | 22.5 g | Oral                   | Acute          | Plasma            | Blood             | Serum samples    |
| H       | Nuttall, 2004 [57]               | 8  | 28        | 23          | 80              | 53                 | Healthy           | Proline          | 6 g    | Oral                   | Acute          | Plasma            | Serum             | Forearm vein     |
|         |                                  | 8  | 28        | 23          | 80              | 53                 | Healthy           | Proline + Glucose| 6 g + 25 g | Oral                   | Acute          | Plasma            | Serum             | Forearm vein     |
|         |                                  | 8  | 28        | 23          | 80              | 53                 | Healthy           | Glucose          | 25 g   | Oral                   | Acute          | Plasma            | Serum             | Forearm vein     |
|         |                                  | 8  | 28        | 23          | 80              | 53                 | Healthy           | Water            |        | -                      |                |                   |                   |                  |
| I       | Nuttall, 2006 [58]               | 6  | 26        | 24          | -               | 59                 | Healthy           | Phenylalanine    | 9.7 g  | Oral                   | Acute          | Plasma            | Serum             | Antecubital vein |
|         |                                  | 6  | 26        | 24          | -               | 59                 | Healthy           | Phenylalanine + Glucose | 9.7 g + 25 g | Oral                   | Acute          | Plasma            | Serum             | Antecubital vein |
|         |                                  | 6  | 26        | 24          | -               | 59                 | Healthy           | Glucose          | 25 g   | Oral                   | Acute          | Plasma            | Serum             | Antecubital vein |
|         |                                  | 6  | 26        | 24          | -               | 59                 | Healthy           | Water            |        | -                      |                |                   |                   |                  |
| J       | Di Sabastiano, 2013 [59]         | 9  | 23.9 ± 1.9| 25 ± 2.4    | 79.4 ± 9       | -                  | Healthy           | Glutamate        | 11.9 g  | Oral                   | Acute          | Serum             | Serum             | Antecubital vein |
|         |                                  | 9  | 23.9 ± 1.9| 25 ± 2.4    | 79.4 ± 9       | -                  | Healthy           | Glutamate (containing NaCl in the same proportions as in the MSG capsules) | -          | Oral                   | Acute          | Serum             | Serum             | Antecubital vein |
| Fernstrom, 1996 [60]                  | 8  | 25.6 ± 4.1| 25.1 ± 1.8 | 79.7 ± 7.5    | -                  | Healthy           | Glutamate         | 12.7 g  | Oral                   | Acute          | Plasma            | Plasma             | -                |
|         |                                  | 8  | 25.6 ± 4.1| 25.1 ± 1.8 | 79.7 ± 7.5    | -                  | Healthy           | Cold flavored vehicle (containing 3 g sodium chloride instead of MSG) | 300 mL    | Oral                   | Acute          | Plasma            | Plasma             | -                |
| Graham, 2000 [61]                     | 9  | 26        | -          | 76.9          | -                  | Healthy           | Glutamate        | 11.5 g  | Oral                   | Acute          | -                 | Plasma             | Antecubital vein |
Table 2. Cont.

| Section | First Author, Year of Publication | n  | Age (yrs) | BMI (kg/m²) | Body Weight (kg) | Lean Body Mass (kg) | Subject Condition | Group                                                                 | Dose | Route of Administration | Duration (min) | Glucose Measurements | Insulin Measurements | Blood Sampling |
|---------|----------------------------------|----|-----------|-------------|-----------------|-------------------|-------------------|-------------------|-------------------|-----------------|-------------------|---------------------|-----------------|
| K       | Zhang, 2011 [62]                 | 5  | 22–25     | 19.7 ± 3    | 61 ± 3          | Healthy          | BCAA (weight ratio of 1.2:3.1:2 for isoleucine:leucine:valine) | 1 g   | Oral                   | Acute           | Plasma            | Plasma              | -                |
|         |                                  | 5  | 22–25     | 19.7 ± 3    | 61 ± 3          | Healthy          | BCAA (weight ratio of 1.2:3.1:2 for isoleucine:leucine:valine) | 5 g   | Oral                   | Acute           | Plasma            | Plasma              | -                |
| G       | Gojda, 2017 [63]                 | 18 | 25.5 ± 1.4| 76.7 ± 2.6  | Healthy        | BCAA (50% leucine, 25% isoleucine, 25% valine) Gelatin Capsule (methylcellulose in gelatin capsule, prepared by University Hospital pharmacy) | 30.7 ± 1.1 g | Oral                   | Acute           | Plasma            | Serum              | -                |
|         |                                  | 18 | 25.5 ± 1.4| 76.7 ± 2.6  | Healthy        | BCAA (43% leucine, 24% isoleucine, 33% valine) Gelatin Capsule (methylcellulose in gelatin capsule, prepared by University Hospital pharmacy) | -     | Oral                   | Acute           | Plasma            | Serum              | -                |
|         |                                  | 18 | 25.5 ± 1.4| 76.7 ± 2.6  | Healthy        | BCAA (equimolar mixture of valine, leucine and isoleucine) | 30.7 ± 1.1 g | IV 0–120                | Plasma           | Serum              |                    | -                |
| T       | Tatpati, 2010 [64]               | 12 | 23.4 ± 0.8| 24.4 ± 1    | 74.5 ± 4.2     | Healthy          | BCAA (equimolar mixture of valine, leucine and isoleucine) | 18.5 g | IV 0–510               | Blood            | Plasma            | Dorsal hand vein arterialized venous blood samples | -                |
|         |                                  | 12 | 70.7 ± 1.1| 24.5 ± 0.7  | 72.7 ± 3.5     | Healthy          | BCAA (equimolar mixture of valine, leucine and isoleucine) | 16.35 g | IV 0–510               | Blood            | Plasma            | Dorsal hand vein arterialized venous blood samples | -                |
|         |                                  | 12 | 23.4 ± 0.8| 24.4 ± 1    | 74.5 ± 4.2     | Healthy          | Saline            | -                 | IV 0–510          | Blood            | Plasma            | Dorsal hand vein arterialized venous blood samples | -                |
|         |                                  | 12 | 70.7 ± 1.1| 24.5 ± 0.7  | 72.7 ± 3.3     | Healthy          | Saline            | -                 | IV 0–510          | Blood            | Plasma            | Dorsal hand vein arterialized venous blood samples | -                |
| L       | Louard, 1990 [65]                | 10 | -         | -           | -               | Healthy          | BCAA (equimolar mixture of valine, leucine and isoleucine) | 3.4 g 2 | IV 0–180               | Blood            | Plasma            | Arterial samples | -                |

1 Estimated based on the average body surface area for males and females [66]. 2 Estimated based on height/weight tables for males and females [67]. 3 Estimated based on average height for males and females [68]. * Two subjects were excluded due to missing time series values. BMI: Body Mass Index, IV: Intravenous, T2DM: Type 2 diabetes mellitus, BCAA: Branched-chain amino acids, n: number of participants, -: Data not reported.
**Effect of leucine intake on glucose and insulin dynamics**

**A. Oral leucine ingestion**

| First author | Subject condition | Amount (g) | Ingestion type | # Subjects | Insulin (μIU/mL) peak, mean, SD (min) | Glucose (mg/dL) peak, mean, SD (min) | Glucose iAUC (mg/dL.min) |
|--------------|------------------|------------|----------------|-----------|--------------------------------------|-------------------------------------|------------------------|
| [8] Kalamipoulou, D | Healthy | 3.6 g | Oral | 10 | 6, 120, 22.0 | 6, 0 | 88.3 |

**B. Oral leucine + glucose ingestion**

| First author | Subject condition | Amount (g) | Ingestion type | # Subjects | Insulin (μIU/mL) peak, mean, SD (min) | Glucose (mg/dL) peak, mean, SD (min) | Glucose iAUC (mg/dL.min) |
|--------------|------------------|------------|----------------|-----------|--------------------------------------|-------------------------------------|------------------------|
| [8] Kalamipoulou, D | Healthy | 3.6 g | Oral | 10 | 6, 120, 22.0 | 6, 0 | 88.3 |}

**C. Intravenous leucine infusion**

| First author | Subject condition | Amount (g) | Ingestion type | # Subjects | Insulin (μIU/mL) peak, mean, SD (min) | Glucose (mg/dL) peak, mean, SD (min) | Glucose iAUC (mg/dL.min) |
|--------------|------------------|------------|----------------|-----------|--------------------------------------|-------------------------------------|------------------------|
| [15] Ahmed, NN | Healthy | 3.6 g | N-infusion | 10 | 6, 120, 22.0 | 6, 0 | 88.3 |

*Insulin and glucose values were not reported.*

**Figure 2.** Leucine info-graph consisting of study details with postprandial glucose and insulin time-series data and iAUC after oral leucine ingestion (A), leucine co-ingested with glucose (B), and intravenous leucine infusion (C) in healthy individuals. No data are available for T2DM patients, and obese individuals.
Kalogeropoulou et al. [8] demonstrated that co-ingestion of leucine+glucose (Figure 2B) increased the insulin concentration (iAUC, 21.25 μU/mL/min) more than the sum of their individual effects (iAUC, 12.87 and 0.95 μU/mL/min for glucose and leucine ingestion, respectively), and attenuated the glucose response. The insulin concentrations increased more rapidly and reached a higher insulin peak (53.1 μU/mL) after co-ingestion of leucine+glucose compared to glucose ingestion alone (31.0 μU/mL).

The effect of intravenous leucine infusion (Figure 2C) has also been examined in healthy people only [14–17]. Three out of the four studies showed increased insulin (iAUC range, 4.47 to 8.90 μU/mL/min) [14,15,17], and decreased glucose concentrations (iAUC range, −2.52 to −6.31 mg/dL/min) compared to baseline. The study with the lowest intravenous leucine dose did not show increased insulin concentrations (iAUC, −0.45 μU/mL/min) [16]. To our knowledge, no kinetic data are available concerning leucine intake in people with obesity and/or T2DM.

3.3. Isoleucine

Isoleucine study details are provided in Table 2 (section B). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S1. Nuttall et al. [18] demonstrated that oral isoleucine ingestion alone (Supplemental Figure S1A) had no significant effect on insulin concentrations, but decreased glucose (iAUC, −4.15 mg/dL/min) compared to ingestion of water (iAUC, 0.30 mg/dL/min) in healthy individuals. Co-ingestion of isoleucine+glucose (Supplemental Figure S1B) increased the insulin concentrations (iAUC, 21.38 μU/mL/min) more than the sum of their individual effects (iAUC, 19.0 and 0.00 μU/mL/min for glucose, and isoleucine ingestion respectively), and attenuated the glucose-stimulated glucose response in healthy individuals [18]. To our knowledge, no kinetic data are available concerning intravenous isoleucine infusion, nor for isoleucine intake in people with obesity and/or T2DM.

3.4. Alanine

Alanine study details are provided in Table 2 (section C). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S2. The effect of oral alanine ingestion has been examined in healthy individuals [19–22], T2DM patients [22], and obese individuals [23] (Supplemental Figure S2A). All four studies showed increased insulin concentrations (iAUC range, 1.01 to 10.53 μU/mL/min) from baseline following oral ingestion of alanine in healthy individuals. Alanine was found to lower glucose concentrations (iAUC, −3.33 mg/dL/min) in one study [21] that had the highest alanine dose. Genueth et al. [22] demonstrated that the effect of oral ingestion of alanine on insulin is dose-dependent, with high dosing (33.8 g) leading to a larger postprandial insulin response (iAUC, 10.53 μU/mL/min) compared to low dosing (6.8 g) (iAUC, 1.01 μU/mL/min). Plasma glucose concentrations were unchanged in both interventions, with the exception of a slight but significant decrease in glucose concentrations 240 min after oral ingestion for the low alanine dose. The initial insulin response to oral alanine ingestion was similar in healthy individuals and T2DM patients, but the insulin concentrations remained elevated over a prolonged period of time in the latter [22]. Glucose concentrations were decreased (iAUC range, −12.99 to −12.29 mg/dL/min) from baseline in T2DM patients. Oral ingestion of alanine also increased insulin (iAUC, 42.67 μU/mL/min), and decreased glucose concentrations (iAUC, −10.49 mg/dL/min) from baseline in people with obesity [23]. To our knowledge, no kinetic data are available concerning co-ingestion of alanine with glucose in individuals.

Additionally, the effect of intravenous alanine infusion was examined in healthy [19,24] and obese individuals [24] (Supplemental Figure S2C). Rossini et al. [19] showed that, in contrast to oral alanine ingestion, intravenous alanine infusion did not alter insulin and glucose concentrations from baseline. Asano et al. [24] showed increased insulin concentrations in both obese participants (iAUC, 12.02 μU/mL/min) and healthy individuals (iAUC, 3.42 μU/mL/min). Glucose concentrations were also increased, despite not being different between groups.
3.5. Glutamine

Glutamine study details are provided in Table 2 (section D). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S3. Greenfield et al. [25] demonstrated that oral ingestion of glutamine increased insulin concentrations compared to ingestion of water only in healthy, T2DM and obese individuals (Supplemental Figure S3A). The effects found were most pronounced in T2DM individuals (iAUC, 13.35 and −0.23 μU/mL/min for glutamine, and water ingestion, respectively), intermediate in obese individuals (iAUC, 6.16 and −2.73 μU/mL/min for glutamine, and water ingestion, respectively), and modest in healthy individuals (iAUC, 1.62 and −1.06 μU/mL/min for glutamine, and water ingestion, respectively). The glucose concentrations were comparable to water ingestion in these groups. To our knowledge, no kinetic data are available concerning individuals co-ingesting glutamine with glucose, nor for intravenous glutamine infusion.

3.6. Arginine

Arginine study details are provided in Table 2 (section E). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S4. The effects of oral arginine ingestion have been investigated in healthy individuals only [26,27] (Supplemental Figure S4A). One out of the two studies [27], with the largest oral arginine dose, showed increased insulin concentrations (iAUC, 1.41 μU/mL/min) compared to water intake (iAUC, 0.06 μU/mL/min), with no significant effect on glucose concentrations.

Co-ingestion of arginine+glucose (Supplemental Figure S4B) resulted in a similar iAUC for insulin compared to glucose ingestion alone and attenuated the glucose-stimulated glucose response [26]. Despite the lower insulin peak, the insulin concentrations remained elevated for a longer time after co-ingestion of arginine+glucose. Tang et al. [27] showed a non-significant increase in insulin concentrations when glucose was co-ingested with arginine (iAUC, 28.62 μU/mL/min) compared to glucose ingestion alone (iAUC, 19.05 μU/mL/min). Glucose concentrations were unchanged.

The effect of intravenous arginine infusion has been examined in healthy individuals [17,28–46], T2DM patients [42–45,47–50], and obese individuals [46,51–53] (Supplemental Figure S4C). All twenty studies [17,28–46] on intravenous arginine infusion in healthy individuals showed increased insulin concentrations (iAUC range, 1.58 to 45.75 μU/mL/min) from baseline. Glucose concentrations increased (iAUC range, 1.79 to 18.65 mg/dL/min) from baseline in fourteen studies [17,28,29,31,33–35,38–43,45]. Four additional studies showed an increase in glucose concentrations in the beginning of the study followed by a drop below baseline, resulting in a negative iAUC [36,37,44,46]. Two studies [30,32] included an intravenous saline infusion control group and showed increased insulin concentrations after intravenous arginine infusion (iAUC, 11.42 and 25.98 μU/mL/min, respectively) compared to intravenous saline infusion (iAUC, −0.64 and 5.33 μU/mL/min, respectively). Broglio et al. [30] also showed increased glucose concentrations (iAUC, 4.45 mg/dL/min) after intravenous arginine infusion compared to intravenous saline infusion (iAUC, −1.64 mg/dL/min); however, no dynamic data were provided for both insulin and glucose. Dela et al. [31] found that intravenous arginine infusion increased insulin and glucose concentrations from baseline in trained and untrained, healthy individuals, with lower insulin concentrations in trained males (iAUC, 18.40 μU/mL/min and 45.75 μU/mL/min, for trained and untrained individuals respectively). The glucose concentrations did not differ between the two groups.

All eight studies [42–45,47–50] investigating intravenous arginine infusion in T2DM individuals showed increased insulin (iAUC range, 4.09 to 21.66 μU/mL/min) and glucose concentrations (iAUC range, 5.00 to 29.75 mg/dL/min). Three studies [43–45] demonstrated that insulin responses were lower in T2DM patients (iAUC range, 4.09 to 13.17 μU/mL/min) compared to healthy individuals (iAUC range, 21.84 to 31.25 μU/mL/min) during intravenous arginine infusion. Efendić et al. [42] demonstrated a slightly lower insulin response in T2DM patients (iAUC, 21.66 μU/mL/min) compared to healthy individuals (iAUC, 22.49 μU/mL/min) who received intravenous arginine infusion, but the insulin concentrations remained elevated over a prolonged period of time in
T2DM patients. Glucose concentrations were increased from baseline in both healthy individuals (iAUC, 5.04 mg/dL/min) and T2DM patients (iAUC, 8.44 mg/dL/min). All four studies [46,51-53] on intravenous arginine infusion in obese individuals showed increased insulin (iAUC range, 6.10 to 22.07 µU/mL/min) and glucose concentrations (iAUC range, 1.37 to 9.08 mg/dL/min). Maccario et al. [46] demonstrated that the arginine induced insulin response was higher in obese participants (iAUC, 22.07 µU/mL/min) than in healthy individuals (iAUC, 8.30 µU/mL/min). Glucose concentrations did not decrease below baseline values in obese participants (iAUC, 1.60 mg/dL/min) compared to healthy individuals (iAUC, −3.20 mg/dL/min).

3.7. Lysine

Lysine study details are provided in Table 2 (section F). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S5. The effects of oral lysine ingestion [54] (Supplemental Figure S5A) and intravenous lysine infusion [17] (Supplemental Figure S5C) were examined in healthy individuals. Kalogeropoulou et al. [54] demonstrated that oral ingestion of lysine increased insulin (iAUC, 0.67 µU/mL/min) and decreased glucose concentrations (iAUC, −1.73 mg/dL/min) compared to individuals that ingested water (iAUC, −0.62 µU/mL/min, 0.35 mg/dL/min). Co-ingestion of lysine+glucose (Supplemental Figure S5B) resulted in a similar iAUC for insulin compared to glucose ingestion alone and attenuated the glucose-stimulated glucose response. However, insulin concentrations increased more rapidly and reached higher peak insulin concentrations (38.7 µU/mL) compared to glucose ingestion alone (35.4 µU/mL).

Intravenous lysine infusion (Supplemental Figure S5C) increased insulin (iAUC, 8.83 µU/mL/min) and decreased glucose concentrations (iAUC, −2.23 mg/dL/min) from baseline in healthy individuals [17]. To our knowledge, no kinetic data are available concerning lysine intake in people with obesity and/or T2DM.

3.8. Glycine

Glycine study details are provided in Table 2 (section G). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S6. The effects of oral glycine ingestion have been examined in healthy individuals [55,56] (Supplemental Figure S6A). One out of the two studies showed increased insulin concentrations (iAUC, 2.29 µU/mL/min) compared to water (iAUC, −1.66 µU/mL/min), with no change in glucose concentrations [55]. Co-ingestion of glycine+glucose (Supplemental Figure S6B) resulted in a similar iAUC for insulin compared to glucose ingestion alone and attenuated the glucose-stimulated glucose response. However, insulin concentrations increased more slowly and reached lower peak insulin concentrations (76.7 µU/mL) compared to glucose ingestion alone (92.4 µU/mL). To our knowledge, no kinetic data are available concerning intravenous glycine infusion, nor for glycine intake in people with obesity and/or T2DM patients.

3.9. Proline

Proline study details are provided in Table 2 (section H). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S7. Nuttall et al. [57] demonstrated that oral ingestion of proline (Supplemental Figure S7A) increased insulin (iAUC, 0.46 µU/mL/min) compared to intake of water (iAUC, −0.99 µU/mL/min), with no change in glucose concentrations in healthy individuals. Co-ingestion of proline+glucose (Supplemental Figure S7B) resulted in a comparable iAUC for insulin compared to glucose ingestion alone, and attenuated the glucose-stimulated glucose response. However, insulin concentrations increased more rapidly and reached higher peak insulin concentrations (41.2 µU/mL) compared to glucose ingestion alone (33.0 µU/mL) in healthy individuals. To our knowledge, no kinetic data are available concerning intravenous proline infusion, nor for proline intake in people with obesity and/or T2DM patients.
3.10. Phenylalanine

Phenylalanine study details are provided in Table 2 (section I). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S8. The effect of oral phenylalanine ingestion [58] (Supplemental Figure S8A) and intravenous phenylalanine infusion [17] (Supplemental Figure S8C) has been examined in healthy individuals. Nuttal et al. [58] found that oral phenylalanine ingestion increased insulin concentrations (iAUC, 3.88 μU/mL/min) compared to water (iAUC, −1.52 μU/mL/min), while glucose concentrations remained unaltered. Co-ingestion of phenylalanine+glucose (Supplemental Figure S8B) resulted in a similar iAUC for insulin compared to glucose ingestion alone, and attenuated the glucose-stimulated glucose response. However, insulin concentrations increased more rapidly and reached higher peak insulin concentrations (64.8 μU/mL) compared to glucose ingestion alone (49.3 μU/mL). Finally, intravenous phenylalanine infusion increased insulin (iAUC, 6.48 μU/mL/min), and decreased glucose concentrations (iAUC, −2.89 mg/dL/min) from baseline in healthy individuals [17]. To our knowledge, no kinetic data are available concerning phenylalanine intake in people with obesity and/or T2DM.

3.11. Glutamate

Glutamate study details are provided in Table 2 (section J). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S9. The effects of oral glutamate ingestion have been examined in healthy individuals only [59–61] (Supplemental Figure S9A). Two out of three studies showed that oral glutamate ingestion increased insulin concentrations (iAUC range, 1.95 to 3.80 μU/mL/min) from baseline [60,61]. Fernstrom et al. [60] showed increased insulin concentrations (iAUC, 1.95 μU/mL/min) after oral glutamate ingestion, compared to the control, whereas the control (a cold flavored vehicle containing 3 g sodium chloride instead of glutamate) did not (iAUC, −0.95 μU/mL/min). Glucose values were not reported. Di Sebastian [59] showed a non-significant increase in insulin (iAUC, 1.70 μU/mL/min) compared to the control group (gelatin capsules containing NaCl) (iAUC, 0.21 μU/mL/min). Glucose concentrations were unchanged compared to the control group. To our knowledge, no kinetic data are available concerning intravenous glutamate infusion, nor for glutamate intake in people with obesity and/or T2DM patients.

3.12. Branched-Chain Amino Acids

BCAA study details (including BCAA composition) are provided in Table 2 (section K). The time series data and the calculated kinetic parameters are visualized in Supplemental Figure S10. The effect of oral BCAA ingestion (mixtures containing leucine, isoleucine, and valine) has been investigated in healthy individuals only [62,63] (Supplemental Figure S10A). Both studies (excluding the low dose, 1 g, BCAA dose intervention [62]), showed that oral BCAA ingestion increased insulin (iAUC range, 0.47 to 1.51 μU/mL/min), and decreased glucose concentrations (iAUC, −9.22 to −3.67 mg/dL/min) from baseline and the control group (iAUC, −0.29 μU/mL/min, −0.30 mg/dL/min). Furthermore, the 5 g BCAA dose resulted in a higher insulin peak concentration (8.5 μU/mL) than the 1 g BCAA dose (7.3 μU/mL) [62]. The highest insulin response was observed in the study that had the largest BCAA dose [63].

The effect of intravenous BCAA infusion (mixtures containing leucine, isoleucine, and valine) has also been investigated in healthy individuals [63–65] (Supplemental Figure S10C). Two out of the three studies showed increased insulin (iAUC range, 0.18 to 0.50 μU/mL/min) [63,64]. Glucose concentrations consistently decreased from baseline in these studies (iAUC, range, −12.05 to −8.37 mg/dL/min). Gojda et al. [63] demonstrated that oral BCAA ingestion increased insulin concentrations (iAUC, 1.51 μU/mL/min) more than the same dose (30.7 g) infused intravenously in healthy individuals (iAUC, 0.42 μU/mL/min). Glucose concentrations declined in the same pattern...
during both BCAA tests. To our knowledge, no kinetic data are available concerning BCAA intake in people with obesity and/or T2DM.

4. Discussion

Amino acids (AAs) have been recognized as important factors involved in glucose homeostasis. In the present systematic review, we aimed to provide a detailed overview of the quantitative effects of oral ingestion and intravenous administration of AAs on postprandial glucose and insulin concentrations in humans. A summary of the results is provided in Table 3.

| AA                      | Oral ingestion | Co-ingestion with glucose | Intravenous infusion |
|-------------------------|----------------|---------------------------|---------------------|
|                         | Healthy        | T2DM                      | Obese               | Healthy        | Healthy        | T2DM                      | Obese               |
| I                       | G              | I                          | G                   | I              | G              | I                          | G                   |
| Leucine                 | +              | +/-                        | ++                  | -              | +              | -                          | -                   |
| Isoleucine              | +/-            | -                          | ++                  | -              | +              | -                          | -                   |
| Alanine                 | ++             | -                          | ++                  | -              | +              | +                          | ++                  |
| Glutamine               | ++             | +/-                        | ++                  | +/-            | -              | ++                         | ++                  |
| Arginine                | +              | +/-                        | +/-                 | +/-            | ++             | ++                         | ++                  |
| Lysine                  | ++             | -                          | +/-                 | -              | ++             | ++                         | ++                  |
| Glycine                 | +              | +/-                        | +/-                 | -              | ++             | ++                         | ++                  |
| Proline                 | ++             | +/-                        | +/-                 | -              | ++             | ++                         | ++                  |
| Phenylalanine           | ++             | +/-                        | ++                  | -              | ++             | ++                         | ++                  |
| Glutamate               | +              | +/-                        | +                   | -              | +              | -                          | -                   |
| BCAA mixture            | +              | -                          | +                   | -              | +              | -                          | -                   |

AA: Amino acid, T2DM: Type 2 diabetes mellitus, BCAA: Branched-chain amino acids, G: Glucose concentrations, I: Insulin concentrations. An overview of the studies is provided in Table 2.

In total, 55 studies that assessed the effects of 10 AAs, i.e., leucine, isoleucine, alanine, glutamine, arginine, lysine, glycine, proline, phenylalanine, glutamate, and BCAA mixtures were included in this review. The majority of orally ingested AAs, except isoleucine, induced an insulin response when ingested in isolation. Glucose concentrations, with the exception of isoleucine, and lysine, remained unchanged.

The increase in insulin concentrations through AAs has long been recognized, though their mechanisms of action are diverse and not yet fully elucidated [4,69]. It has been shown that AAs affect β-cell insulin secretion through mitochondrial metabolism linked to the tricarboxylic acid (TCA) cycle, and subsequent generation of ATP (e.g., for leucine, glutamine, and alanine) [70,71]. The rise in the ATP/ADP ratio suppresses ATP-sensitive potassium channels, causing depolarization of the β-cell plasma membrane. This in turn activates voltage-gated Ca^{2+} channels and through the influx of Ca^{2+} leads to insulin exocytosis. Other AAs, like arginine via its mCAT2A AA transporter, directly depolarize the β-cell plasma membrane [4,72]. Co-transport of AA with Na^{+} (e.g., alanine, and proline) also depolarizes the β-cell plasma membrane, ultimately leading to Ca^{2+} activated insulin exocytosis [69,73–75]. The seemingly unaffected glucose concentrations despite the presence of an insulin response are somewhat surprising. However, compensatory glucagon production and gluconeogenesis to prevent hypoglycemia may at least partly explain these observations [76].
Indeed, multiple studies included in the present systematic review showed increased glucagon concentrations after ingestion of isolated AAs [8,18,19,24–26,28,29,31,34,36,43,45,48,50,53–55,58]. Digitizing postprandial glucagon responses found in these studies was, however, outside the scope of the present review. Furthermore, the carbon chain of AA can be used in the liver for gluconeogenesis (i.e., generating glucose from non-carbohydrate carbon substrates), which might further contribute to the lack in suppression of postprandial glucose concentrations [25].

While oral ingestion of most AAs did not alter postprandial glucose responses, oral intake of isoleucine, lysine, and BCAA mixtures evoked a clear decrease in plasma glucose concentrations. Remarkably, the decrease in glucose concentration following isoleucine ingestion occurred without a change in insulin concentrations, suggesting glucose uptake by tissues independent of insulin, as has previously been found in vivo [77]. In the latter study, isoleucine increased glucose uptake in rat skeletal muscle cells through activation of phosphatidylinositol 3-kinase, and independent of mTOR, indicative of insulin-independent glucose uptake.

Co-ingestion of most identified AAs (lysine, glycine, proline, phenylalanine) with glucose did not significantly increase the insulin response compared to the ingestion of glucose alone. However, for these AAs, co-ingestion with glucose prompted a reduction in the glucose response of up to ~70% for phenylalanine. The mechanisms remain to be determined, as it is unclear whether the attenuation of glucose is due to an increased removal rate of glucose (i.e., insulin-independent mechanisms), or due to decreased endogenous glucose production by the liver [55]. Despite the unchanged insulin responses (iAUCs), the postprandial insulin dynamics were frequently altered, indicating a sharper, and more pronounced peak after co-ingestion of AAs (i.e., lysine, proline, and phenylalanine) with glucose as compared to glucose ingesting alone. The greater early rise in insulin concentrations observed after co-ingestion of AAs may imply increased first-phase insulin secretion [54,58], which certainly influences the postprandial glucose concentrations. Co-ingestion of glucose with leucine or isoleucine increased the postprandial insulin concentrations more than the sum of their individual effects, reaching a ~50% increase in iAUC for leucine [8]. This synergistic stimulating effect of the combined intake of AAs and glucose on plasma insulin concentrations was already described by Floyd et al. [6] many years ago. Maximizing insulin secretion could be important in the treatment of T2DM to promote glucose disposal and improve glucose homeostasis [69]. Van Loon et al. [9] showed that co-ingestion of a mixture of protein hydrolysate, leucine, and phenylalanine in long-term T2DM patients, resulted in a considerable (+189%) increase in insulin response compared to the healthy control group (+114%), implying functional β-cells’ secretory capacity to stimuli other than glucose. Manders et al. [78] applied continuous infusion with labeled [6,6-3H2] glucose to determine blood glucose appearance and disappearance rates following carbohydrate ingestion with or without addition of a protein, leucine, and phenylalanine mixture in T2DM patients. A substantial (~3-fold) greater insulin response was observed following co-ingestion of carbohydrates with AA/protein, with a 28% reduction in blood glucose response, attributed to an increase in plasma glucose disposal.

Intravenous infusion of leucine, arginine, lysine, phenylalanine, and BCAA infusion induced a plasma insulin response and, with the exception of arginine, evoked a decrease in plasma glucose concentrations. These AAs were thus able to induce a substantial increase in insulin response, also observed after oral ingestion, independent from the gut. However, intravenous alanine infusion, unlike oral alanine ingestion, did not induce an insulin response, suggesting that alanine may increase postprandial insulin concentrations through an incretin effect [19]. An incretin effect indicates the release of insulin-inducing substances from the gut and plays a major part in the regulation of postprandial glucose concentrations [79,80]. Incretin hormones, like gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are shown to rapidly stimulate insulin secretion from β-cells in response to nutrients in order to control meal-related glycemic excursions [81]. This incretin effect was also observed by others [82,83], demonstrating that oral ingestion of an AA mixture increased insulin concentrations more than comparable intravenous AA infusion, with increased GIP concentrations. A large number of studies were found that had investigated the effects of intravenous
arginine infusion, which is often used to evaluate β-cell function (i.e., during hyperglycemic clamp) and allows for simultaneous examination of acute insulin, c-peptide, and glucagon response [84]. Intravenous arginine infusion stimulated insulin release to a greater extent than oral arginine ingestion; however, studies comparing oral and intravenous administrations are lacking. The larger arginine content in the blood circulation, by avoiding gut metabolism, might have led to increased β-cell stimulation [85,86].

Although limited data are available on the effect of AAs on glucose and insulin responses across different population, studies in obese and T2DM individuals focused on alanine, glutamine, and arginine. Abnormalities in β-cell function are present in prediabetes and T2DM, whereas insulin sensitivity already declines decades before T2DM onset [87]. Furthermore, insulin resistance through excess adiposity is linked to several abnormalities, impacting β-cell function and viability [4]. The studies included here showed that AAs are able to stimulate insulin secretion and lower glucose concentrations in T2DM, and obese individuals. Greenfield et al. [25] observed the greatest insulin response after oral glutamine ingestion in T2DM patients, followed by obese and healthy people. In addition, increased GLP-1 concentrations were found following oral ingestion of glutamine, with no significant differences between T2DM, obese, and healthy individuals. Samocha-Bonet et al. [88] showed that, in patients with well-controlled T2DM, the stimulatory action of GLP-1 on insulin secretion is preserved, reducing postprandial glycemia in T2DM [89]. Whereas oral ingestion of alanine resulted in a comparable insulin response in both healthy and T2DM patients, the insulin dynamics showed considerable differences. More specific, a lower but prolonged elevation in insulin concentrations was observed in T2DM patients [22]. This prolonged elevation in insulin was also observed in obese individuals following intravenous alanine infusion [24]. Intravenous infusion of arginine showed a blunted insulin response in T2DM, as compared to healthy individuals, in three out the four studies. This impairment in insulin secretion might be explained by insufficient β-cell mass, and/or functional defects within the β-cells themselves, in patients with T2DM and individuals at risk for diabetes [4].

In this review, we systematically investigated the effects of AAs on postprandial insulin and glucose dynamics. An extensive approach, consisting of the extraction and utilization of time series data, with a focus on the link between glucose and insulin kinetics, was employed. In the present review, the effects of ten distinct AAs and BCAA mixtures from 55 articles were included. As the AA composition in protein and whole foods largely contributes to the variability observed in glycemic responses, we decided to focus on the glycemic effects of individual AAs. However, the diversity of the included studies, e.g., differences in study set-up, participant characteristics, and measurement instruments, made it difficult to draw quantitative conclusions based on the data. Furthermore, the large heterogeneity in AA dosages used in the studies was not accounted for, when calculating and comparing the postprandial responses, as this would incorrectly assume a linear relationship between AA dosage and postprandial glucose and insulin responses, which we believe is not true. Nevertheless, this might have contributed to a certain extent to the variability observed in postprandial glucose and insulin responses between the different studies. While glucagon measurements were outside the scope of the present systematic review, future studies investigating the effect of AAs on glucose and insulin responses should also include postprandial glucagon concentrations. Notably, since we have made the digitized data on insulin and glucose concentrations publicly available, other parameters such as glucagon concentrations can easily be incorporated in this database. A large difference in the number of identified studies per AA was found in the literature. There was ample information on some AAs (e.g., 28 articles on arginine) and very little information on others (e.g., 1 article on isoleucine), yet several distinct effects were found for the studied AAs. Furthermore, a better understanding of the effects of different AAs on postprandial plasma glucose and insulin responses, as well as putative synergistic effects of co-ingestion of different AAs with glucose, may contribute to the development of more optimal dietary intervention to improve (postprandial) glucose homeostasis.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/10/3211/s1,
File S1: PubMed search strategy, Figure S1: Isoleucine infograph, Figure S2: Glutamine infograph, Figure S4: Arginine infograph, Figure S5: Lysine infograph, Figure S6: Glycine infograph, Figure S7: Proline infograph, Figure S8: Phenylalanine infograph, Figure S9: Glutamate infograph, Figure S10: BCAA infograph.

Author Contributions: Conceptualization, B.v.S., G.H.G., M.L., N.v.R. and I.C.W.A.; Methodology, B.v.S., G.H.G., B.E., M.L., N.v.R. and I.C.W.A.; Software, B.v.S.; Validation, B.v.S.; Formal Analysis, B.v.S.; Investigation, B.v.S.; Resources, I.C.W.A.; Data Curation, B.v.S.; Writing—Original Draft Preparation, B.v.S.; Writing—Review & Editing, B.v.S., G.H.G., B.E., M.L., N.v.R. and I.C.W.A.; Visualization, B.v.S. and B.E.; Supervision, G.H.G., and I.C.W.A.; Project Administration, I.C.W.A.; Funding Acquisition, M.L., N.v.R. and I.C.W.A. All authors have read and agreed to the published version of the manuscript.

Funding: This project was organized by and executed under the auspices of TiFN, a public-private partnership on precompetitive research in food and nutrition. The authors have declared that no competing interest exist in the writing of this publication. Funding for this research was obtained from the Netherlands Organization for Scientific Research (ALWTF.2016.021).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Pena, M.J.; Rocha, J.C.; Borges, N. Amino acids, glucose metabolism and clinical relevance for phenylketonuria management. Ann. Nutr. Disord. Ther. 2015, 2, 1026.
2. Röder, P.V.; Wu, B.; Liu, Y.; Han, W. Pancreatic regulation of glucose homeostasis. Exp. Mol. Med. 2016, 48, e219. [CrossRef] [PubMed]
3. Bröer, S.; Bröer, A. Amino acid homeostasis and signalling in mammalian cells and organisms. Biochem. J. 2017, 474, 1935–1963. [CrossRef] [PubMed]
4. Newsholme, P.; Krause, M. Nutritional regulation of insulin secretion: Implications for diabetes. Clin. Biochem. Rev. 2012, 33, 35. [PubMed]
5. Floyd, J.; Fajans, S.S.; Conn, J.W.; Knopf, R.F.; Rull, J. Stimulation of insulin secretion by amino acids. J. Clin. Invest. 1966, 45, 1487–1502. [CrossRef]
6. Floyd, J.C.; Fajans, S.S.; Pek, S.; Thiffault, C.A.; Knopf, R.F.; Conn, J.W. Synergistic effect of essential amino acids and glucose upon insulin secretion in man. Diabetes 1970, 19, 109–115. [CrossRef]
7. Nilsson, M.; Holst, J.J.; Björck, I.M. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: Studies using glucose-equivalent drinks. Am. J. Clin. Nutr. 2007, 85, 996–1004. [CrossRef]
8. Kalogeropoulou, D.; LaFave, L.; Schweim, K.; Gannon, M.C.; Nuttall, F.Q. Leucine, when ingested with glucose, synergistically stimulates insulin secretion and lowers blood glucose. Metab. Clin. Exp. 2008, 57, 1747–1752. [CrossRef]
9. van Loon, L.J.; Kruiswijk, M.; Menheere, P.P.; Wagenmakers, A.J.; Saris, W.H.; Keizer, H.A. Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care 2003, 26, 625–630. [CrossRef]
10. Kovatchev, B.P.; Breton, M.; Man, C.D.; Cobelli, C. In silico preclinical trials: A proof of concept in closed-loop control of type 1 diabetes. J. Diabetes Sci. Technol. 2009, 3, 44–55. [CrossRef]
11. MATLAB. R2018b; The MathWorks Inc.: Natick, MA, USA, 2018.
12. Wilkinson, D.J.; Hossain, T.; Hill, D.; Phillips, B.; Crossland, H.; Williams, J.; Loughna, P.; Churchward-Venne, T.; Breen, L.; Phillips, S.M. Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism. J. Physiol. 2013, 591, 2911–2923. [CrossRef] [PubMed]
13. Yoshii, N.; Sato, K.; Ogasawara, R.; Nishimura, Y.; Shinohara, Y.; Fujita, S. Effect of Mixed Meal and Leucine Intake on Plasma Amino Acid Concentrations in Young Men. Nutrients 2018, 10, 1543. [CrossRef] [PubMed]
14. Abumrad, N.N.; Robinson, R.P.; Gooch, B.R.; Lacy, W. The effect of leucine infusion on substrate flux across the human forearm. J. Surg. Res. 1982, 32, 453–463. [CrossRef]
15. Eriksson, L.S.; Hagenfeldt, L.; Felig, P.; Wahren, J. Leucine uptake by splanchnic and leg tissues in man: Relative independence of insulin levels. Clin. Sci. 1983, 65, 491–498. [CrossRef] [PubMed]
16. Sherwin, R.S. Effect of starvation on the turnover and metabolic response to leucine. J. Clin. Investig. 1978, 61, 1471–1481. [CrossRef] [PubMed]
17. Floyd, J.C., Jr.; Fajans, S.S.; Pek, S.; Thiffault, C.A.; Knopf, R.F.; Conn, J.W. Synergistic effect of certain amino acid pairs upon insulin secretion in man. Diabetes 1970, 19, 102–108. [CrossRef]
18. Nuttall, F.Q.; Schweim, K.; Gannon, M.C. Effect of orally administered isoleucine with and without glucose on insulin, glucagon and glucose concentrations in non-diabetic subjects. Eur. J. Clin. Nutr. Metab. 2008, 3, e152–e158. [CrossRef]
19. Rossini, A.A.; Aoki, T.T.; Ganda, O.P.; Soeldner, J.S.; Cahill, G.F., Jr. Alanine-induced amino acid interrelationships. Metabolism 1975, 24, 1185–1192. [CrossRef]
20. Rose, D.P.; Leklem, J.E.; Fardal, L.; Baron, R.B.; Shrago, E. Effect of oral alanine loads on the serum triglycerides of oral contraceptive users and normal subjects. Am. J. Clin. Nutr. 1977, 30, 691–694. [CrossRef]
21. Sato, T.; Saito, S.; Kokubun, M.; Saito, T.; Ito, M.; Yamamoto, M.; Kaise, K.; Kaise, N. Gluconeogenesis from glycerol and alanine in thyrotoxicosis. Tohoku J. Exp. Med. 1980, 132, 369–373. [CrossRef]
22. Genuth, S.M.; Castro, J.E. Effect of oral alanine on blood beta-hydroxybutyrate and plasma glucose, insulin, free fatty acids, and growth hormone in normal and diabetic subjects. Metabolism 1974, 23, 375–386. [CrossRef]
23. Genuth, S.M. Effects of oral alanine administration in fasting obese subjects. Metabolism 1973, 22, 927–937. [CrossRef]
24. Asano, T.; Ninomiya, H.; Kan, K.; Yamamoto, T.; Okumura, M. Plasma glucagon response to intravenous alanine in obese and non-obese subjects. Endocrinol. Ipn. 1989, 36, 767–773. [CrossRef] [PubMed]
25. Greenfield, J.R.; Farooqi, I.S.; Keogh, J.M.; Henning, E.; Habib, A.M.; Blackwood, A.; Reimann, F.; Holst, J.J.; Gribble, F.M. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am. J. Clin. Nutr. 2008, 89, 106–113. [CrossRef] [PubMed]
26. Gannon, M.C.; Nuttall, J.A.; Nuttall, F.Q. Oral arginine does not stimulate an increase in insulin concentration but delays glucose disposal. Am. J. Clin. Nutr. 2002, 76, 1016–1022. [CrossRef]
27. Tang, Z.Q.; Wu, T.; Cui, S.W.; Zhu, X.H.; Yin, T.; Wang, C.F.; Zhu, J.Y.; Wu, A.J. Stimulation of insulin secretion by large-dose oral arginine administration in healthy adults. Exp. Ther. Med. 2013, 6, 248–252. [CrossRef]
28. Giugliano, D.; Marfella, R.; Verrazzo, G.; Acampora, R.; Coppola, L.; Cozzolino, D.; D’Onofrio, F. The vascular effects of L-Arginine in humans. The role of endogenous insulin. J. Clin. Investig. 1997, 99, 433–438. [CrossRef]
29. Coiro, V.; Volpi, R.; Capretti, L.; Speroni, G.; Caffarri, G.; Chiodera, P. Involvement of nitric oxide in arginine, but not glucose, induced insulin secretion in normal men. Clin. Endocrinol. 1997, 46, 115–119. [CrossRef]
30. Broglio, F.; Gottero, C.; Benso, A.; Prodam, F.; Destefanis, S.; Gauna, C.; Maccario, M.; Deghenghi, R.; van der Lely, A.; Ghigo, E. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J. Clin. Endocrinol. Metab. 2003, 88, 4268–4272. [CrossRef]
31. Dela, F.; Mikines, K.J.; Tronier, B.; Galbo, H. Diminished arginine-stimulated insulin secretion in trained men. J. Appl. Physiol. 1990, 69, 261–267. [CrossRef]
32. Penny, R.; Blizzard, R.M.; Davis, W.T. Sequential study of arginine monochloride and normal saline as stimuli to growth hormone release. Metabolism 1970, 19, 165–169. [CrossRef]
33. Levin, S.R.; Karam, J.H.; Hane, S.; Grodsky, G.M.; Forsham, P.H. Enhancement of arginine-induced insulin secretion in man by prior administration of glucose. Diabetes 1971, 20, 171–176. [CrossRef] [PubMed]
34. Bratusch-Marrain, P.; Björkman, O.; Hagenfeldt, L.; Walderhäll, W.; Wahren, J. Influence of arginine on splanchnic glucose metabolism in man. Diabetes 1979, 28, 126–131. [CrossRef] [PubMed]
35. Imura, H.; Seino, Y.; Ikeda, M.; Taminato, T.; Miyamoto, Y.; Goto, Y. Impaired plasma insulin response to arginine in hyperthyroidism: Important role of the rise of blood glucose in the second phase of insulin release induced by arginine. Diabetes 1976, 25, 961–968. [CrossRef] [PubMed]
36. Hasselblatt, M.; Krampe, H.; Jacobs, S.; Sindram, H.; Armstrong, V.W.; Hecker, M.; Ehrenreich, H. Arginine challenge unravels persistent disturbances of urea cycle and gluconeogenesis in abstinent alcoholics. Alcohol Alcohol. 2006, 41, 372–378. [CrossRef]
37. Berger, W.; Stahl, M.; Ohnhäus, E.; Goschke, H. Pancreatic glucagon, plasma insulin and blood glucose responses to arginine infusion in nondiabetic subjects following biguanide pretreatment. Horm. Metab. Res. 1974, 6, 165. [CrossRef]
38. Dupre, J.; Curtis, J.D.; Waddell, R.W.; Beck, J.C. Alimentary factors in the endocrine response to administration of arginine in man. *Lancet* 1968, 2, 28–29. [CrossRef]

39. Dupre, J.; Curtis, J.D.; Unger, R.H.; Waddell, R.W.; Beck, J.C. Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. *J. Clin. Investig.* 1969, 48, 745–757. [CrossRef]

40. Kimber, J.; Watson, L.; Mathias, C.J. Cardiovascular and neurohormonal responses to i. v. l-arginine in two groups with primary autonomic failure. *J. Neurol.* 2001, 248, 1036–1041. [CrossRef]

41. Oneda, A.; Sato, M.; Matsuda, K.; Yanbe, A.; Maruhama, Y. Plasma glucagon response to blood glucose fall, gastrointestinal hormones and arginine in man. *Tohoku J. Exp. Med.* 1972, 107, 241–251. [CrossRef]

42. Efendić, S.; Cerasi, E.; Luft, R. Quantitative study on the potentiating effect of arginine on glucagon-induced insulin response in healthy, prediabetic, and diabetic subjects. *Diabetes* 1974, 23, 161–171. [CrossRef] [PubMed]

43. Kawamori, R.; Shichiri, M.; Kikuchi, M.; Yamasaki, Y.; Abe, H. Perfect normalization of excessive glucagon responses to intravenous arginine in human diabetes mellitus with the artificial beta-cell. *Diabetes* 1980, 29, 762–765. [CrossRef] [PubMed]

44. Sparks, L.L.; Copinschi, G.; Donaldson, C.L.; Blum, A.S.; Forsham, P.H. Hyperglycemic response to intravenous arginine in prematurity-onset diabetes. *Am. Diabetes Assoc.* 1967, 16, 268–271. [CrossRef] [PubMed]

45. Kawamori, R.; Shichiri, M.; Kikuchi, M.; Yamasaki, Y.; Abe, H. The mechanism of exaggerated glucagon response to arginine in diabetes mellitus. *Diabetes Res. Clin. Pract.* 1985, 1, 131–137. [CrossRef]

46. Maccario, M.; Grottoli, S.; Razzore, P.; Procopio, M.; Oleandri, S.E.; Ciccarelli, E.; Camanni, F.; Ghigo, E. Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. *Eur. J. Endocrinol.* 1996, 135, 205–210. [CrossRef]

47. Marfella, R.; Acampora, R.; Verrazzo, G.; Ziccardi, P.; de Rosa, N.; Giunta, R.; Giugliano, D. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. *Diabetes Care* 1996, 19, 934–939. [CrossRef]

48. Raskin, P.; Aydin, I.; Unger, R.H. Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. *Diabetes* 1976, 25, 227–229. [CrossRef] [PubMed]

49. Maejima, K.; Himeno, M.; Ishibashi, T.; Nakano, S.; Nishio, M.; Uchida, K. Paradoxical decrease in plasma nox by l-arginine load in diabetic and non-diabetic subjects. *Clin. Exp. Hypertens.* 2002, 24, 155–167. [CrossRef]

50. Ohneda, A.; Ishii, S.; Horigome, K.; Yamagata, S. Glucagon response to arginine after treatment of diabetes mellitus. *Diabetes* 1975, 24, 811–819. [CrossRef] [PubMed]

51. Carpentier, A.; Giacca, A.; Lewis, G. Effect of increased plasma non-esterified fatty acids (NEFAs) on arginine-stimulated insulin secretion in obese humans. *Diabetologia* 2001, 44, 1989–1997.

52. Maccario, M.; Grottoli, S.; Procopio, M.; Oleandri, S.; Boffano, G.; Savio, P.; Camanni, F.; Ghigo, E. Effects of cholinergic blockade by pirenzepine on insulin and glucose response to oral and intravenous glucose and to arginine load in obesity. *J. Endocrinol. Invest.* 1997, 20, 8–12. [CrossRef] [PubMed]

53. Walter, R.M., Jr.; Gold, E.M.; Michas, C.A.; Ensinck, J.W. Portal and peripheral vein concentrations of insulin and glucagon after arginine infusion in morbidly obese subjects. *Metabolism* 1980, 29, 1037–1040. [CrossRef]

54. Kalogeropoulos, D.; LaFave, L.; Schweim, K.; Gannon, M.C.; Nuttall, F.Q. Lysine ingestion markedly attenuates the glucose response to ingested glucose without a change in insulin response. *Am. J. Clin. Nutr.* 2009, 90, 314–320. [CrossRef] [PubMed]

55. Gannon, M.C.; Nuttall, J.A.; Nuttall, F.Q. The metabolic response to ingested glycine. *Am. J. Clin. Nutr.* 2002, 76, 1302–1307. [CrossRef] [PubMed]

56. Kasai, K.; Kobayashi, M.; Shimoda, S.-I. Stimulatory effect of glycine on human growth hormone secretion. *Metabolism* 1978, 27, 201–208. [CrossRef]

57. Nuttall, F.Q.; Gannon, M.C.; Jordan, K. The metabolic response to ingestion of proline with and without glucose. *Metabolism* 2004, 53, 241–246. [CrossRef] [PubMed]

58. Nuttall, F.; Schweim, K.; Gannon, M. Effect of orally administered phenylalanine with and without glucose on insulin, glucagon and glucose concentrations. *Horm. Metab. Res.* 2006, 38, 518–523. [CrossRef]

59. Di Sebastiano, K.M.; Bell, K.E.; Barnes, T.; Weeraratne, A.; Premji, T.; Mourtzakis, M. Glutamate supplementation is associated with improved glucose metabolism following carbohydrate ingestion in healthy males. *Br. J. Nutr.* 2013, 110, 2165–2172. [CrossRef]
60. Fernstrom, J.D.; Cameron, J.L.; Fernstrom, M.H.; McConaha, C.; Weltzin, T.E.; Kaye, W.H. Short-term neuroendocrine effects of a large oral dose of monosodium glutamate in fasting male subjects. J. Clin. Endocrinol. Metab. 1996, 81, 184–191.

61. Graham, T.E.; Skro, V.; Friars, D.; Gibala, M.J. Glutamate ingestion: The plasma and muscle free amino acid pools of resting humans. Am. J. Physiol. Endocrinol. Metab. 2000, 278, E83–E89. [CrossRef]

62. Zhang, Y.; Kobayashi, H.; Mawatari, K.; Sato, J.; Bajotto, G.; Kitaora, Y.; Shimomura, Y. Effects of branched-chain amino acid supplementation on plasma concentrations of free amino acids, insulin, and energy substrates in young men. J. Nutr. Sci. Vitaminol. 2011, 57, 114–117. [CrossRef]

63. Gojda, J.; Strakova, R.; Plihalova, A.; Tuma, P.; Potockova, J.; Polak, J.; Andel, M. Increased Incretin but not Insulin Response after Oral versus Intravenous Branched Chain Amino Acids. Ann. Nutr. Metab. 2017, 70, 293–302. [CrossRef] [PubMed]

64. Tatpati, L.L.; Irving, B.A.; Tom, A.; Bigelow, M.L.; Klaus, K.; Short, K.R.; Nair, K.S. The effect of branched chain amino acids on skeletal muscle mitochondrial function in young and elderly adults. J. Clin. Endocrinol. Metab. 2010, 95, 894–902. [CrossRef] [PubMed]

65. Louard, R.J.; Barrett, E.J.; Gelfand, R.A. Effect of infused branched-chain amino acids on muscle and whole-body amino acid metabolism in man. Clin. Sci. 1990, 79, 457–466. [CrossRef]

66. Mosteller, R.D. Simplified calculation of body-surface area. N. Engl. J. Med. 1987, 317, 1098.

67. Metropolitan Life Insurance Company, Health and Safety Education Division. 1983 metropolitan height and weight tables. Stat. Bull. Metrop. Life Found 1983, 64, 3–9.

68. Fryar, C.D.; Kruszans-Moran, D.; Gu, Q.; Ogden, C.L. Mean Body Weight, Weight, Waist Circumference, and Body Mass Index among Adults: United States, 1999–2000 through 2015–2016; Centers for Disease Control and Prevention: Hyattsville, MD, USA, 2018.

69. Van Loon, C.; Luc, J. Amino acids as pharmaco-nutrients for the treatment of type 2 diabetes. ImmunoL Endocr. Metab. Agents Med. Chem. 2007, 7, 39–48. [CrossRef]

70. Penten, U.; Kriegstein, E.; Poser, W.; Schönborn, J.; Hasselblatt, A. Effects of L-leucine and alpha-ketoisocaproic acid upon insulin secretion and metabolism of isolated pancreatic islets. FEBS Lett. 1972, 20, 225–228.

71. Newsholme, P.; Gaudel, C.; McClanaghan, N. Nutrient regulation of insulin secretion and β-cell functional integrity. Adv. Exp. Med. Biol. 2010, 654, 91–114.

72. Sener, A.; Best, L.C.; Yates, A.P.; Kadiata, M.M.; Olivares, E.; Louchami, K.; Jijakli, H.; Ladrière, L.; Malaisse, W.J. Stimulus-secretion coupling of arginine-induced insulin release. Endocrine 2000, 13, 329–340. [CrossRef]

73. Dunne, M.J.; Yule, D.I.; Gallacher, D.V.; Petersen, O.H. Effects of alanine on insulin-secreting cells: Patch-clamp and single cell intracellular Ca2+ measurements. Biochim. Biophys. Acta 1990, 1055, 157–164. [CrossRef]

74. McClanaghan, N.H.; Barnett, C.R.; Flatt, P.R. Na+ cotransport by metabolizable and nonmetabolizable amino acids stimulates a glucose-regulated insulin-secretory response. Biochem. Biophys. Res. Commun. 1998, 249, 299–303. [CrossRef] [PubMed]

75. Newsholme, P.; Brennan, L.; Bender, K. Amino acid metabolism, β-cell function, and diabetes. Diabetes 2006, 55 (Suppl. S2), S39–S47. [CrossRef]

76. Bankir, L.; Bouby, N.; Speth, R.C.; Velho, G.; Crambert, G. Glucagon revisited: Coordinated actions on the liver and kidney. Diabetes Res. Clin. Pract. 2018, 146, 119–129. [CrossRef] [PubMed]

77. Doi, M.; Yamaoka, I.; Fukunaga, T.; Nakayama, M. Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes. Biochem. Biophys. Res. Commun. 2003, 312, 1111–1117. [CrossRef] [PubMed]

78. Manders, R.J.; Wagenmakers, A.J.; Koopman, R.; Zorenc, A.H.; Menheere, P.P.; Schaper, N.C.; Saris, W.H.; van Loon, L.J. Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am. J. Clin. Nutr. 2005, 82, 76–83. [CrossRef]

79. Holst, J.J.; Gribble, F.; Horowitz, M.; Rayner, C.K. Roles of the Gut in Glucose Homeostasis. Diabetes Care 2016, 39, 884–892. [CrossRef]

80. Nauck, M.A.; Meier, J.J. The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016, 4, 525–536. [CrossRef]

81. Gérard, C.; Vidal, H. Impact of Gut Microbiota on Host Glycemic Control. Front. Endocrinol. (Lausanne) 2019, 10, 29. [CrossRef]
82. Lindgren, O.; Pacini, G.; Tura, A.; Holst, J.J.; Deacon, C.F.; Ahrén, B. Incretin effect after oral amino acid ingestion in humans. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 1172–1176. [CrossRef]

83. Abdulla, H.; Bass, J.J.; Stokes, T.; Gorissen, S.H.M.; McGlory, C.; Phillips, B.E.; Phillips, S.M.; Smith, K.; Idris, I.; Atherton, P.J. The effect of oral essential amino acids on incretin hormone production in youth and ageing. *Endocrinol. Diabetes Metab.* **2019**, *2*, e00085. [CrossRef] [PubMed]

84. Robertson, R.P.; Bogachus, L.D.; Oseid, E.; Parazzoli, S.; Patti, M.E.; Rickels, M.R.; Schuetz, C.; Dunn, T.; Pruett, T.; Balamurugan, A.N.; et al. Assessment of β-cell mass and α- and β-cell survival and function by arginine stimulation in human autologous islet recipients. *Diabetes* **2015**, *64*, 565–572. [CrossRef] [PubMed]

85. Tangphao, O.; Grossmann, M.; Chalon, S.; Hoffman, B.B.; Blaschke, T.F. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. *Br. J. Clin. Pharmacol.* **1999**, *47*, 261–266. [CrossRef]

86. Castillo, L.; Chapman, T.E.; Yu, Y.M.; Ajami, A.; Burke, J.F.; Young, V.R. Dietary arginine uptake by the splanchnic region in adult humans. *Am. J. Physiol.* **1993**, *265*, E532–E539. [CrossRef] [PubMed]

87. Roden, M.; Shulman, G.I. The integrative biology of type 2 diabetes. *Nature* **2019**, *576*, 51–60. [CrossRef]

88. Samocha-Bonet, D.; Wong, O.; Synnott, E.-L.; Piayaratna, N.; Douglas, A.; Gribble, F.M.; Holst, J.J.; Chisholm, D.J.; Greenfield, J.R. Glutamine Reduces Postprandial Glycemia and Augments the Glucagon-Like Peptide-1 Response in Type 2 Diabetes Patients. *J. Nutr.* **2011**, *141*, 1233–1238. [CrossRef]

89. Wang, X.; Liu, H.; Chen, J.; Li, Y.; Qu, S. Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. *Int. J. Endocrinol.* **2015**, *2015*, 651757. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).